Patent intelligence · US
US 10626147
Cell penetrating peptides and methods of making and using thereof
Cell penetrating peptides and methods of making and using thereof
Patent details — US 10626147
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 21, 2020
- Expiration
- Apr 16, 2040
- Applicant
- Entrada Therapeutics, Inc.
- Claims
- 22
- CPC classes
- A61K, A61K38/00, A61K38/05, A61K38/12
Quick answer
US 10626147 (Cell penetrating peptides and methods of making and using thereof) is held by Entrada Therapeutics, Inc.. Status: granted. Granted Apr 21, 2020. Expires Apr 16, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Entrada Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K38/00, A61K38/05, A61K38/12, A61K38/465, A61K47/64
More from Entrada Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11987821
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
granted -
US 11225506
Cell penetrating peptides and methods of making and using thereof
granted -
US 11168310
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
granted -
US 10815276
Cell penetrating peptides and methods of making and using thereof
granted
Frequently asked questions
What is US patent 10626147?
US 10626147 (Cell penetrating peptides and methods of making and using thereof) is held by Entrada Therapeutics, Inc.. Status: granted. Granted Apr 21, 2020. Expires Apr 16, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10626147?
Entrada Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 10626147 expire?
Our index shows an expiration date of Apr 16, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.